Medical Developments International Limited
(ASX:MVP) has received regulatory approval in Singapore.
MVP has obtained approval from the Health Sciences Authority of Singapore to market and sell its inhaled analgesic product ‘Penthrox’.
Penthrox can be used for trauma and associated pain, as well as pain in surgical procedures in adults and has sold more than 5 million units in Australia.
Under the approval, Penthrox can be sold effective immediately via MVP’s Singapore partner, Link Healthcare Singapore Pte. Ltd.
Medical Developments International Limited reported a net profit of $1.53 million in FY15.
